Drug Marketing Authorisation Holders Invited to Participate in China's Public Testing of Patent Listing Platform
The Center for Drug Evaluation (CDE) under NMPA (National Medical Products Administration) of China recently issued a notice stating that the patent information listing platform related to the early resolution mechanism of drug-related patent disputes has been released for public testing, which marks a substantial step toward the implementation of China's drug patent linkage system.
The notice urged drug marketing authorisation holders that have been authorised for marketing in China to actively participate in the public testing. The patent information as listed duly during the testing period, after confirmation by the relevant marketing authorisation holder, will be published and serve as the basis of the patent declaration to be made by the applicant of a chemical generic drug, a traditional Chinese medicine with the same name and formula or a biosimilar.
